Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables - Other (2016 - 2025)

Historic Receivables - Other for Ascendis Pharma A (ASND) over the last 10 years, with Q4 2025 value amounting to $17.0 million.

  • Ascendis Pharma A's Receivables - Other rose 6926.93% to $17.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.0 million, marking a year-over-year increase of 6926.93%. This contributed to the annual value of $16.5 million for FY2025, which is 6431.88% up from last year.
  • Ascendis Pharma A's Receivables - Other amounted to $17.0 million in Q4 2025, which was up 6926.93% from $10.0 million recorded in Q4 2024.
  • In the past 5 years, Ascendis Pharma A's Receivables - Other registered a high of $23.0 million during Q4 2021, and its lowest value of $10.0 million during Q4 2024.
  • Its 5-year average for Receivables - Other is $16.7 million, with a median of $17.0 million in 2025.
  • As far as peak fluctuations go, Ascendis Pharma A's Receivables - Other skyrocketed by 1037756.08% in 2021, and later crashed by 5119.16% in 2024.
  • Over the past 5 years, Ascendis Pharma A's Receivables - Other (Quarter) stood at $23.0 million in 2021, then tumbled by 43.04% to $13.1 million in 2022, then soared by 56.93% to $20.5 million in 2023, then plummeted by 51.19% to $10.0 million in 2024, then soared by 69.27% to $17.0 million in 2025.
  • Its last three reported values are $17.0 million in Q4 2025, $10.0 million for Q4 2024, and $20.5 million during Q4 2023.